UV-Trichoscopic Red Fluorescence in Alopecia Areata

August 31, 2026 updated by: Sevgi Nazli Apucu, Istanbul Training and Research Hospital

Evaluation of UV-Trichoscopic Red Fluorescence Intensity in Relation to Trichoscopic Findings and Response to Intralesional Corticosteroid Treatment in Limited Plaque-Type Alopecia Areata

The goal of this observational study is to learn whether red fluorescence seen with ultraviolet (UV) trichoscopy is related to disease findings and treatment response in adults with limited plaque-type alopecia areata. Trichoscopy is a close-up imaging method used to examine the hair and scalp. The study will investigate whether the amount of red fluorescence at the beginning of the study is related to how soon hair starts to grow back, how much hair regrows, and how trichoscopic findings change during follow-up. Participants for whom intralesional corticosteroid treatment has been planned as part of their regular medical care will have standard trichoscopic and UV-trichoscopic images taken of the affected scalp area. They will be followed at weeks 4, 8, and 12, when hair regrowth and changes in scalp and hair findings will be evaluated. Researchers will measure red fluorescence in the images and examine whether it is related to treatment response over time.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a prospective observational cohort study involving adults with limited plaque-type alopecia areata who are receiving intralesional corticosteroid treatment as part of routine clinical care. Participation in the study does not determine whether a patient receives intralesional corticosteroid treatment.

At baseline, the affected scalp area will be evaluated using conventional polarized trichoscopy and UV-trichoscopy. Follow-up assessments will be performed at weeks 4, 8, and 12 using the same imaging approach. Trichoscopic findings of interest will include yellow dots, black dots, exclamation mark hairs, and broken hairs.

UV-trichoscopic red fluorescence will be assessed quantitatively by measuring red-channel intensity on standardized digital images. Imaging and image analysis procedures will be performed using a standardized acquisition protocol to improve comparability between visits.

Treatment response will be evaluated according to the appearance and extent of visible hair regrowth and the change in trichoscopic activity findings during follow-up. The main analysis will examine whether baseline red fluorescence intensity is associated with the timing and magnitude of response to intralesional corticosteroid treatment. Associations between red fluorescence intensity and baseline trichoscopic findings, as well as changes in fluorescence intensity and trichoscopic findings over time, will also be evaluated.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Sevgi Nazli Apucu, Dermatology Resident Physician
  • Phone Number: +905374048180
  • Email: snapucu@gmail.com

Study Locations

  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye)
        • Recruiting
        • Istanbul Training and Research Hospital
        • Contact:
          • Sevgi Nazli Apucu, Dermatology Resident Physician
          • Phone Number: +905374048180
          • Email: snapucu@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adults with limited plaque-type alopecia areata of the scalp who are receiving intralesional corticosteroid treatment as part of routine clinical care at the dermatology outpatient clinic will be prospectively enrolled. Participants will undergo standardized conventional trichoscopic and UV-trichoscopic assessments and will be followed for 12 weeks to evaluate red fluorescence intensity, trichoscopic findings, and hair regrowth.

Description

Inclusion Criteria:

  • Age 18 years or older
  • Limited plaque-type alopecia areata of the scalp
  • Active hair loss
  • Symptom onset within the previous 6 months
  • No topical, intramuscular, or oral treatment for alopecia areata within the previous 1 month
  • No intralesional corticosteroid treatment within the previous 6 weeks
  • Provision of informed consent

Exclusion Criteria:

  • Beard alopecia areata
  • Very extensive alopecia areata or multiple large plaques
  • Tinea capitis or active infection
  • Current phototherapy
  • Systemic immunosuppressive treatment within the washout period specified in the study protocol
  • Pregnancy or breastfeeding
  • Contraindication to UV imaging

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Limited Plaque-Type Alopecia Areata
Adults with limited plaque-type alopecia areata who are receiving intralesional corticosteroid treatment as part of routine clinical care. Participants will undergo conventional trichoscopic and UV-trichoscopic assessments at baseline and during follow-up at weeks 4, 8, and 12. Hair regrowth, trichoscopic findings, and UV-trichoscopic red fluorescence intensity will be evaluated over time.
Drug: Triamcinolone Acetonide
Intralesional triamcinolone acetonide is administered for limited plaque-type alopecia areata as part of routine clinical care. The decision to administer treatment is made independently of participation in this observational study. The study prospectively evaluates trichoscopic and UV-trichoscopic findings and hair regrowth during routine treatment follow-up.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Timing of First Visible Hair Regrowth
Time Frame: Baseline through week 12
Baseline UV-trichoscopic red fluorescence intensity will be quantified from standardized digital images using red-channel intensity measurements. Participants will be evaluated for the first appearance of visible hair regrowth at follow-up visits at weeks 4, 8, and 12. The association between baseline red fluorescence intensity and the timing of first visible hair regrowth will be assessed.
Baseline through week 12
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Degree of Hair Regrowth
Time Frame: Weeks 4, 8, and 12
The degree of hair regrowth will be assessed at follow-up visits using standardized clinical photographs and trichoscopic images of the alopecic plaque. Hair regrowth will be evaluated according to the proportion of the baseline alopecic area showing visible regrowth, with trichoscopic examination used to identify early or fine regrowing hairs that may not be clearly visible in clinical photographs. The association between baseline UV-trichoscopic red fluorescence intensity and the degree of hair regrowth will be evaluated.
Weeks 4, 8, and 12

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in UV-Trichoscopic Red Fluorescence Intensity During Follow-up
Time Frame: Baseline and weeks 4, 8, and 12
UV-trichoscopic red fluorescence intensity will be quantified from standardized digital images using red-channel intensity measurements. Changes in red fluorescence intensity from baseline through follow-up visits will be evaluated
Baseline and weeks 4, 8, and 12
Change in Trichoscopic Activity Findings During Follow-up
Time Frame: Baseline and weeks 4, 8, and 12
Trichoscopic activity findings, including yellow dots, black dots, exclamation mark hairs, and broken hairs, will be recorded using standardized trichoscopic images. Changes in these findings during follow-up will be evaluated.
Baseline and weeks 4, 8, and 12
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Trichoscopic Findings
Time Frame: Baseline
The association between baseline UV-trichoscopic red fluorescence intensity and baseline trichoscopic findings, including yellow dots, black dots, exclamation mark hairs, and broken hairs, will be evaluated.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Training and Research Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Vildan Manav, Istanbul Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 31, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 4, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IstanbulTRH-DERM-AAUV-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings